Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTIMAS: 1-Year Pembrolizumab for Advanced Melanoma
NCT07376317Phase 2Active, not recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Dec 2021
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by Instituto do Câncer do Estado de São Paulo. Started Dec 2021; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07376317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376317.